Clinical Trial Update: A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies [Phase 1]

View source ↗

Summary

A Phase I trial of donor-derived 19-28z CAR T cells following allogeneic transplant for CD19 malignancies has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Leukemia
• Lymphoma

Drugs mentioned

• Donor-derived 19-28z CAR T cells (19-28z CAR T cells)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Leukemia, Lymphoma | Phase 1 | Status: WITHDRAWN